How astrocyte proteins cause white-matter injury in blood-vessel-related dementia

Astrocytic WNK-SPAK-NKCC1 Cascade in White Matter Astrogliosis and Injury

NIH-funded research Louisiana State Univ Hsc Shreveport · NIH-11318968

This work looks at whether a chain of proteins in brain support cells leads to white-matter damage and memory problems in people with vascular-related cognitive decline.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionLouisiana State Univ Hsc Shreveport NIH-funded
Lab location1 site (Shreveport, United States)
Project IDNIH-11318968 on NIH RePORTER

What this research studies

The team uses mouse models that mimic chronic blood-flow problems to reproduce the white-matter and hippocampal damage seen in vascular contributions to cognitive impairment and dementia. They track activation of a specific protein chain (WNK-SPAK-NKCC1) in astrocytes, the brain's support cells, in affected white matter and hippocampus. The researchers will manipulate this pathway in the lab to see if changing its activity alters tissue injury and cognitive outcomes in the models. Findings aim to reveal how astrocyte signaling leads to myelin loss, axonal disruption, and astrogliosis.

Who could benefit from this research

Good fit: People with vascular contributions to cognitive impairment or dementia, especially those with white-matter lesions or a history of blood-vessel disease affecting the brain, would be the eventual candidates for therapies based on this work.

Not a fit: Patients with dementia caused purely by non-vascular processes or those seeking immediate clinical treatment are unlikely to benefit directly from this preclinical research right now.

Why it matters

Potential benefit: If successful, this could identify a new drug target to prevent or reduce white-matter injury and cognitive decline from vascular causes.

How similar studies have performed: Prior laboratory studies have linked NKCC1-related signaling to cell swelling and injury, but applying this specific astrocyte WNK-SPAK-NKCC1 pathway toward treatments is a newer and less-tested approach.

Where this research is happening

Shreveport, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Acquired brain injuryAtherosclerotic Cardiovascular Disease
Last reviewed 2026-06-10 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.